These findings suggest that increased RAC3 levels may contribute to the acquisition of resistance to a spectrum of treatments, including chemotherapy, targeted therapies, and immunotherapies, within bladder cancer. This evidence concerns the gene RAC3 and urinary bladder carcinoma.